LncRNA EPIC1 promotes tumor angiogenesis via activating the Ang2/Tie2 axis in non-small cell lung cancer

Hou, Yanjiao; Jia, Hengmin; Cao, Yunxia; Zhang, Shuang; Zhang, Xiaolei; Wei, Pingping; Xie, Jun; Dong, Wenting; Wang, Baolong

doi:10.1016/j.lfs.2020.118933

Cited by 15 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…120 Elevated Lnc-EPIC1 expression stimulated angiogenesis by activating the Ang2/Tie2 pathway, and furthermore, Lnc-EPIC1 overexpression simultaneously enhanced new blood vessel formation in vivo. 120 Abbreviations: EZH2, enhancer of zeste homolog 2; LATS2, large tumor suppressor kinase 2; LIMK2b, Lin11, Isl-1, and Mec-3 kinase 2b; lncRNA, long noncoding RNA; NSCLC, nonsmall cell lung cancer; PCAT6, prostate cancer-associated transcript 6; SCLC, small cell lung cancer; SNHG20, small nucleolar RNA host gene 20; Sox2ot, SOX2 overlapping transcript; SPRY4-IT1, SPRY4 intronic transcript 1; TUG1, taurine upregulated gene 1. Unequivocally, metastasis and angiogenesis are central topics in cancer, with lncRNAs participating in lung cancer metastasis by regulating angiogenesis.…”

Section: Lncrnas Involved In Angiogenesismentioning

confidence: 99%

Revisiting Lung Cancer Metastasis: Insight From the Functions of Long Non-coding RNAs

Huang

Zhu

Liang

et al. 2021

Technol Cancer Res Treat

View full text Add to dashboard Cite

Globally, lung cancer is the most common cause of cancer-related deaths. After diagnosis at all stages, <7% of patients survive for 10 years. Thus, diagnosis at later stages and the lack of effective and personalized drugs reflect a significant need to better understand the mechanisms underpinning lung cancer progression. Metastasis should be responsible for the high lethality and recurrence rates seen in lung cancer. Metastasis depends on multiple crucial steps, including epithelial–mesenchymal transition, vascular remodeling, and colonization. Therefore, in-depth investigations of metastatic molecular mechanisms can provide valuable insights for lung cancer treatment. Recently, long noncoding RNAs (lncRNAs) have attracted considerable attention owing to their complex roles in cancer progression. In lung cancer, multiple lncRNAs have been reported to regulate metastasis. In this review, we highlight the major molecular mechanisms underlying lncRNA-mediated regulation of lung cancer metastasis, including (1) lncRNAs acting as competing endogenous RNAs, (2) lncRNAs regulating the transduction of several signal pathways, and (3) lncRNA coordination with enhancer of zeste homolog 2. Thus, lncRNAs appear to execute their functions on lung cancer metastasis by regulating angiogenesis, autophagy, aerobic glycolysis, and immune escape. However, more comprehensive studies are required to characterize these lncRNA regulatory networks in lung cancer metastasis, which can provide promising and innovative novel therapeutic strategies to combat this disease.

show abstract

Section: Lncrnas Involved In Angiogenesismentioning

confidence: 99%

Revisiting Lung Cancer Metastasis: Insight From the Functions of Long Non-coding RNAs

Huang

Zhu

Liang

et al. 2021

Technol Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…( 53 ) found that overexpression of PVT1 in NSCLC can inhibit downstream expression of miR-29c while increasing expression of VEGF and CD31, which are closely related to angiogenesis and poor prognosis of NSCLC. In addition, the lncRNA EPIC1 is significantly upregulated in NSCLC tissues and cell lines, where it stimulates the formation and proliferation of HUVEC tubes and promotes tumor angiogenesis by activating the Ang2/Tie2 pathway ( 54 ). Ang2 has been reported to disrupt vascular stability and act synergistically with VEGF-A to promote angiogenesis ( 57 ).…”

Section: Novel Angiogenic Regulators In Lung Cancer Treatmentmentioning

confidence: 99%

Novel Angiogenic Regulators and Anti-Angiogenesis Drugs Targeting Angiogenesis Signaling Pathways: Perspectives for Targeting Angiogenesis in Lung Cancer

Lin

Wang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Lung cancer growth is dependent on angiogenesis. In recent years, angiogenesis inhibitors have attracted more and more attention as potential lung cancer treatments. Current anti-angiogenic drugs targeting VEGF or receptor tyrosine kinases mainly inhibit tumor growth by reducing angiogenesis and blocking the energy supply of lung cancer cells. However, these drugs have limited efficiency, raising concerns about limited scope of action and mechanisms of patient resistance to existing drugs. Therefore, current basic research on angiogenic regulators has focused more on screening carcinogenic/anticancer genes, miRNAs, lncRNAs, proteins and other biomolecules capable of regulating the expression of specific targets in angiogenesis signaling pathways. In addition, new uses for existing drugs and new drug delivery systems have received increasing attention. In our article, we analyze the application status and research hotspots of angiogenesis inhibitors in lung cancer treatment as a reference for subsequent mechanistic research and drug development.

show abstract

“…v1 exerts these functions by sponging miR-511-5p as a ceRNA. Hou et al (2021) reported that lncRNA EPIC1 is significantly upregulated in NSCLC tissues and cells. EPIC1 silence represses Ang2 -Tie2 signaling pathway-related proteins, thereby inhibiting HUVECs (human umbilical vein endothelial cell) proliferation and channel forming abilities.…”

Section: The Tumor Vasculature Is Supported By Lncrnasmentioning

confidence: 99%

Long Non-Coding RNAs in Lung Cancer: The Role in Tumor Microenvironment

Dai

Liu

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The development of various therapeutic interventions, particularly immune checkpoint inhibitor therapy, have effectively induced tumor remission for patients with advanced lung cancer. However, few cancer patients can obtain significant and long-lasting therapeutic effects for the limitation of immunological nonresponse and resistance. For this case, it’s urgent to identify new biomarkers and develop therapeutic targets for future immunotherapy. Over the past decades, tumor microenvironment (TME)-related long non-coding RNAs (lncRNAs) have gradually become well known to us. A large number of existing studies have indicated that TME-related lncRNAs are one of the major factors to realize precise diagnosis and treatment of lung cancer. Herein, this paper discusses the roles of lncRNAs in TME, and the potential application of lncRNAs as biomarkers or therapeutic targets for immunotherapy in lung cancer.

show abstract

LncRNA EPIC1 promotes tumor angiogenesis via activating the Ang2/Tie2 axis in non-small cell lung cancer

Cited by 15 publications

References 32 publications

Revisiting Lung Cancer Metastasis: Insight From the Functions of Long Non-coding RNAs

Revisiting Lung Cancer Metastasis: Insight From the Functions of Long Non-coding RNAs

Novel Angiogenic Regulators and Anti-Angiogenesis Drugs Targeting Angiogenesis Signaling Pathways: Perspectives for Targeting Angiogenesis in Lung Cancer

Long Non-Coding RNAs in Lung Cancer: The Role in Tumor Microenvironment

Contact Info

Product

Resources

About